Jonsson, Philip
Bandlamudi, Chaitanya
Cheng, Michael L.
Srinivasan, Preethi
Chavan, Shweta S.
Friedman, Noah D.
Rosen, Ezra Y.
Richards, Allison L.
Bouvier, Nancy
Selcuklu, S. Duygu
Bielski, Craig M.
Abida, Wassim
Mandelker, Diana
Birsoy, Ozge
Zhang, Liying
Zehir, Ahmet
Donoghue, Mark T. A.
Baselga, José
Offit, Kenneth
Scher, Howard I.
O’Reilly, Eileen M.
Stadler, Zsofia K.
Schultz, Nikolaus
Socci, Nicholas D.
Viale, Agnes
Ladanyi, Marc
Robson, Mark E.
Hyman, David M.
Berger, Michael F.
Solit, David B.
Taylor, Barry S.
Article History
Received: 3 January 2019
Accepted: 12 June 2019
First Online: 10 July 2019
Change Date: 11 December 2019
Change Type: Correction
Change Details: An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: M.L.C. reports receiving travel/accommodation funding from Allergan, Sanofi-Aventis, and Daiichi Sankyo. W.A. reports receiving honoraria from Caret, advisory board activities for Clovis Oncology, Janssen, and MORE Health, travel/accommodation expenses from Clovis Oncology and GlaxoSmithKline, and research funding from AstraZeneca, Zenith Epigenetics, Clovis Oncology, and GlaxoSmithKline. L.Z. reports receiving honoraria from Future Technology Research LLC, Roche Diagnostics Asia Pacific, BGI, and Illumina. L.Z. has a family member with a leadership position and ownership interest in Shanghai Genome Center. J.B. is an employee of AstraZeneca, serves on the Board of Directors of Foghorn and is a past board member of Varian Medical Systems, Bristol-Myers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Lilly, Seragon, Novartis and Northern Biologics. He has stock or other ownership interests in Tango and Venthera, for which he is a co-founder. He has previously received honoraria or travel expenses from Roche, Novartis, and Lilly. E.M.O. reports receiving consulting fees from BioLineRx, Targovax, Halozyme, Celgene, Cytomx, and Bayer and research funding support from Genentech, Roche, BMS, Halozyme, Celgene, MabVax Therapeutics, and ActaBiologica. D.M.H. reports receiving research funding from AstraZeneca, Puma Biotechnology, and Loxo Oncology and personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiophram Group, and Genetech. M.F.B. reports receiving research funding from Illumina and advisory board activities for Roche. D.B.S. reports advisory board activities for Loxo Oncology, Pfizer, Illumina, Lilly Oncology, Vivideon, and Intezyne. All stated activities were outside of the work described herein. No other disclosures were noted.